


PHARMACEUTICAL 2017



AGILE THERAPEUTICS INC Rank 148 of 313





PHARMACEUTICAL 2017



AGILE THERAPEUTICS INC Rank 148 of 313

The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 167% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is -156%, being 260% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	51,518
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,678
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	-863
Other Liabilities	0
Other Net Income	117
Property and Equipment	12,330
Research and Development	20,929
Revenues	0
Selling, General and Administrative Expense	8,792

Output Variable	Value in 1000 USD
Assets	63,866
Liabilities	10,678
Expenses	28,858
Stockholders Equity	53,188
Net Income	-28,741
Comprehensive Net Income	-28,741
Economic Capital Ratio	-156%